TARSUS PHARMACEUTICALS, INC.— Sankey Diagram
Quarterly mode · period ending 2025-12-31 · SEC EDGAR
ComparingFY2025 (Q4) vs FY2024 (Q4)
Revenue
$152M
↑+128.4% +$85Mvs FY2024 (Q4)
Gross Profit
$152M
↑+128.4% +$85Mvs FY2024 (Q4)
Operating Income
$3M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2025 (Q4) | FY2024 (Q4) |
|---|---|---|
| Revenue | $152M | $66M |
| COGS | $0 | $0 |
| Gross Profit | $152M | $66M |
| R&D | $18M | $17M |
| SG&A | $131M | $69M |
| D&A | $202K | $192K |
| Other OpEx | $0 | $0 |
| Operating Income | $3M | $0 |
| Interest Exp. | $2M | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $535K | $0 |
| Tax | $535K | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · TARS · Comparing FY2025 (Q4) vs FY2024 (Q4)